Evaluation of the effect of carvedilol orodispersible tablets on ischemia-reperfusion injury and flap viability in rats: An in vivo study.

Autor: Tokgonul S; Plastic Surgery Clinic, Etlik City Hospital, Ankara, Turkey., Ozyilmaz ED; Faculty of Pharmacy, Department of Pharmaceutical Technology, Eastern Mediterranean University, Famagusta, North Cyprus, Turkey., Comoglu T; Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkey., Gürbüz MM; Institute of Health Sciences, Ankara University, Ankara, Turkey.; Department of Analytical Chemistry, Faculty of Pharmacy, Medipol University, Ankara, Turkey., Doğan Topal B; Department of Analytical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey., Kocak FE; Department of Medical Biochemistry, Faculty of Medicine, Kütahya Health Sciences University, Kutahya, Turkey., Ozakpinar HR; Plastic Surgery Clinic, Etlik City Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2024 Oct 04, pp. e2400618. Date of Electronic Publication: 2024 Oct 04.
DOI: 10.1002/ardp.202400618
Abstrakt: Flap surgery is an integral part of plastic surgery, and ischemia-reperfusion (I/R) injury significantly affects the viability of the flap. Carvedilol (CRV), a nonselective beta-blocker with alpha-1 blocking and antioxidant properties, and known for its potential in reducing I/R damage, was chosen as the active substance for our study. The aim of this study was to investigate the vasodilator and antioxidant effects of CRV on rat inferior epigastric artery skin flap using orally disintegrating tablets (ODTs). The optimized ODT formulation was subjected to in vivo experiments using Sprague-Dawley female rats (n = 24) divided into three groups: Group I (control, I/R), Group II (treatment, I/R + CRV), and Group III (treatment, I/R), I/R + CRV ODT). Reperfusion was then observed following the release of the microclamp from the pedicle, and the flap was then re-adapted to its original position. Control rats were given oral isotonic solution via gavage and were subjected to 8 h of ischemia and 12 h of reperfusion. Group II was given 2 mg/kg CRV oral tablets for 7 days before and after surgery. Group III was given 2 mg/kg/day CRV ODT for the same period. Biopsies were taken from the flap and histopathological and biochemical analyses including superoxide dismutase, glutathionenitric oxide, malondialdehyde, paraoxonase 1, total oxidant, and total antioxidant capacities were performed. This study demonstrates that CRV ODTs significantly increased flap viability by approximately 25% compared to the control group, highlighting their promising therapeutic potential.
(© 2024 Deutsche Pharmazeutische Gesellschaft.)
Databáze: MEDLINE
Externí odkaz: